Ratings by Cantor Fitzgerald (Eric Schmidt)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/26/2026 | LeonaBio | LONA | New Coverage | Overweight (N/A) |
5.81 (5.30) |
-8.78% | Details | |
| 1/12/2026 | Beam Therapeutics Inc | BEAM | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/19/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/17/2025 | Legend Biotech Corp. | LEGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/11/2025 | Scholar Rock | SRRK | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/25/2025 | Agios Pharma | AGIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/20/2025 | Agios Pharma | AGIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/27/2025 | Tango Therapeutics Inc. | TNGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/20/2025 | Verastem | VSTM | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/20/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/16/2025 | Verastem | VSTM | New Coverage | Overweight (N/A) |
9.40 (6.38) |
-32.13% | Details | |
| 10/9/2025 | Arcellx Inc. | ACLX | New Coverage | Neutral (N/A) |
88.29 (114.33) |
29.49% | Details | |
| 8/14/2025 | Alumis Inc | ALMS | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2025 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Overweight (N/A) |
0.00 (10.42) |
0% | Details | |
| 7/28/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/17/2025 | Scholar Rock | SRRK | New Coverage | Overweight (N/A) |
41.15 (45.29) |
10.06% | Details | |
| 6/27/2025 | Avidity Biosciences | RNA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/24/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/20/2025 | Prothena Corp | PRTA | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/10/2025 | Cidara Therapeutics | CDTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/3/2025 | Bicara Therapeutics Inc | BCAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2025 | Bicara Therapeutics Inc | BCAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2025 | Immatics | IMTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2025 | Agios Pharma | AGIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/2/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/23/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/15/2025 | Cidara Therapeutics | CDTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/10/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/1/2025 | Immatics | IMTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/31/2025 | Bicara Therapeutics Inc | BCAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/31/2025 | Avidity Biosciences | RNA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/27/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/21/2025 | Summit Therapeutics plc | SMMT | New Coverage | Overweight (N/A) |
19.44 (15.11) |
-22.27% | Details | |
| 3/20/2025 | Alumis Inc | ALMS | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/13/2025 | Bicara Therapeutics Inc | BCAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Avidity Biosciences | RNA | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/5/2025 | Biogen | BIIB | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/27/2025 | Cidara Therapeutics | CDTX | New Coverage | Overweight (N/A) |
18.91 (221.38) |
1070.7% | Details | |
| 10/8/2024 | Bicara Therapeutics Inc | BCAX | New Coverage | Overweight (N/A) |
24.45 (18.47) |
-24.46% | Details | |
| 7/23/2024 | Alumis Inc | ALMS | New Coverage | Overweight (N/A) |
13.00 (26.90) |
106.92% | Details | |
| 5/30/2024 | ADC Therapeutics | ADCT | New Coverage | Overweight (N/A) |
3.33 (4.11) |
23.42% | Details | |
| 4/23/2024 | Incyte | INCY | New Coverage | Neutral (N/A) |
51.92 (95.94) |
84.78% | Details | |
| 4/4/2024 | Tango Therapeutics Inc. | TNGX | New Coverage | Overweight (N/A) |
7.68 (16.95) |
120.7% | Details | |
| 3/14/2024 | Avidity Biosciences | RNA | New Coverage | Overweight (N/A) |
24.83 (14.82) |
-40.31% | Details | |
| 2/8/2024 | Agios Pharma | AGIO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/20/2023 | Biogen | BIIB | New Coverage | Overweight (N/A) |
251.69 (184.87) |
-26.55% | Details | |
| 11/9/2023 | Gracell Biotechnologies Inc | GRCL | New Coverage | Overweight (N/A) |
4.40 (10.25) |
132.95% | Details | |
| 11/2/2023 | Immatics | IMTX | New Coverage | Overweight (N/A) |
7.80 (9.86) |
26.41% | Details | |
| 11/2/2023 | Immunocore Holdings | IMCR | New Coverage | Overweight (N/A) |
45.37 (32.94) |
-27.4% | Details | |
| 10/17/2023 | bluebird bio | BLUE | New Coverage | Neutral (N/A) |
2.80 (4.97) |
77.5% | Details |
